Keyword: Daiichi Sankyo


Daiichi Sankyo and Merck & Co. Collaborate on Three DXd ADCs Worldwide

20.10.2023 -

Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where...


AstraZeneca and Daiichi Sankyo in Cancer Drug Deal

06.08.2020 -

UK-Swedish drugmaker AstraZeneca has entered into a global development and commercialization agreement with Daiichi Sankyo, which could be worth up to $6 billion for the...


AstraZeneca in $6.9 Billion Rights Share Deal

03.04.2019 - In a move to accelerate the development of its oncology franchise, AstraZeneca has agreed a $6.9 billion deal with Japanese pharma major Daiichi Sankyo to share rights to a new...


AstraZeneca Sells Gastro Treatment to Swiss Group Tillotts

13.07.2015 - In another move to sharpen its focus on oncology, diabetes and respiratory disorders, AstraZeneca has announced it is selling all non-US rights for Entocort, a treatment for Crohn...


Daiichi Sankyo Unloads Entire Stake in Sun Pharma

23.04.2015 - In a pre-negotiated share sale agreed a year ago, Japan's Daiichi Sankyo has unloaded its entire 8.9% stake in India's mammoth generics producer Sun Pharmaceutical Industries...


India’s Sun Pharmaceutical to Buy Compatriot Ranbaxy

09.04.2014 - Sun Pharmaceutical Industries, India's largest drugmaker by market value, has agreed to buy compatriot generics manufacturer Ranbaxy Laboratories for $3.2 billion from Daiichi...


Daiichi Sankyo Pledges “Bold Action” on Ranbaxy Ban

04.02.2014 - Japan's Daiichi Sankyo said it would send personnel to help resolve problems at a production facility of its drugmaking subsidiary Ranbaxy at Toansa in India's northern state of...


Fourth Ranbaxy Generics Plant Hit by FDA Ban

27.01.2014 - Indian drugmaker Ranbaxy Laboratories faces long delays and high costs in launching big-selling generic drugs in the U.S. after products from a fourth plant were banned due to...